The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...